BMO Capital analyst Gary Nachman lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $66.00 (from $70.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Pacira Pharmaceuticals (PCRX) PT Raised to $95 at BarclaysAugust 5, 2021 4:09 AM Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual ConferenceAugust 4, 2021 8:00 AM Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual ConferenceAugust 4, 2021 8:00 AM Form S-8 Pacira BioSciences, Inc. August 3, 2021 4:32 PM Pacira Pharmaceuticals (PCRX) PT Lowered to $82 at Needham & Company, Following EarningsAugust 3, 2021 3:34 PM Form 10-Q Pacira BioSciences, Inc. For: Jun 30August 3, 2021 11:38 AM Pacira Pharma (PCRX) Tops Q2 EPS by 8cAugust 3, 2021 8:08 AM Form 8-K Pacira BioSciences, Inc. For: Aug 03August 3, 2021 8:03 AM Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021August 3, 2021 8:00 AM